Introduction
Patients with a history of myocardial infarction, stroke, transient ischaemic attack, or unstable angina are at particular risk of vascular death or of a further cardiac or cerebral event. To discover whether this risk can be reduced many randomised clinical trials of various types of antiplatelet treatment have been conducted (table I) .'-3 Such treatment need not be particularly expensive or toxic, so that even risk reductions that were only moderate-for example, altering 16% into 12% recurrences within two years-might be well worth knowing about when considering how to manage an individual patient.
Though such risk reductions might be ofsome practical relevance, however, they are surprisingly easy to miss, even in some of the largest currently available clinical trials. If, for example, such an effect exists then even if 2000 patients were randomised (1000 treated, 1000 control) there would be an even chance of getting a false negative result-that is, of failing to achieve convincing (2p<0-01) levels of statistical significance. If, however, several different antiplatelet trials are considered then their results may usefully reinforce each other, even though the real risk reductions in different trials may be somewhat different. An overview has therefore been attempted of the results of all randomised trials ofprolonged treatment with drugs whose principal purpose is inhibition of platelet aggregation. Such overviews have two main purposes. Firstly and most obviously, they include far larger numbers of patients than individual trials do and hence yield results that are far less subject to random error. Secondly, they avoid the substantial systematic bias that may be engendered when dozens of related trials have been conducted and just a few become well known, for trials may tend to become well known partly because their results are unusually promising (or unusually unpromising). The methods used for this overview never compared 321 patients in one trial directly with patients in another (for not only might the patients have been different but so too might the treatments, durations of treatment, quality of follow up, and end point definitions). Instead, the methods compared only like with like within one trial and did not implicitly assume that the sizes of any risk reductions in different trials must be similar.
Materials and methods
Relevant randomised trials were identified by computer aided search (Medline), by conversation with colleagues (particularly those who had coordinated such studies), by scrutiny of the reference lists of trials and review articles, and by inquiry of various manufacturers of antiplatelet agents. Six trials were still in progress and results were not expected to be available for some time. This review is of the remaining 25 trials (table I) ,-36 which included some 29 000 patients with a history of myocardial infarction, unstable angina, stroke, or transient ischaemic attack. For these trials "intention to treat" analyses of outcome by allocated treatment could be used. The aim was to review the apparent effects of treatment on non-fatal stroke-that is, stroke with survival to the end of the scheduled treatment (7) 61 (20) 67 (23) 49 (24) 43 (25) 46 (31) 8 (6) 125 (9) 75 (14) *Co-dergocrine mesylate also given to patients in these groups.
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Results Table I lists the trials that were identified; the main results were obtained from the principal investigators in most cases. For some trials the data obtained differed slightly from the data originally published. In general this was because considerable efforts were made to seek complete follow up data on all randomised subjects, including not only events while treatment continued but also events before the scheduled end of trial treatment (which was on a common date for all patients in some trials, at a fixed interval after randomisation in others, and at a combination of these two dates in two trials33 36). In some cases this included review of records that had been collected by the trialists but not used, and in others it entailed collection by the trialists of additional records. In neurological trials many patients suffered myocardial infarction and more deaths were attributed to heart disease than to stroke. Conversely, in the heart disease trials many patients suffered a stroke. As antiplatelet treatment might affect either condition, the primary analysis was of the effect of allocated treatment on the odds of suffering at least one important vascular event. Important vascular events were defined as excluding transient ischaemic attacks, angina, and "possible" myocardial infarctions but generally including "definite" strokes that caused symptoms that persisted for at least 24 hours and non-fatal myocardial infarctions that were classified as "probable" or "definite," together with all deaths that might have been vascular or haemorrhagic-that is, ICD (9th revision) codes 390-459, 530-535, 578, and 797-799. There were, of course, slight differences between different studies in how vascular events were categorised, but because retrospective reclassification of many vascular events would have been impracticable the definitions preferred by the original investigators in each study were generally retained. The heterogeneity that this entailed does not bias or invalidate the main overview results (see below).
NON-VASCULAR MORTALITY
When this collaboration was initiated the fundamental purpose was to assess the main effects of treatment on various types of fatal and non-fatal vascular events (stroke, myocardial infarction, and vascular death). Hence deaths were classified merely as "vascular"-that is, possibly or definitely vascular or haemorrhagic-or "non-vascular," with no further subdivision of the non-vascular deaths. If antiplatelet treatment does have some unanticipated protective or adverse effect that might have been disclosed by a cause specific analysis of the non-vascular deaths, a crude overall analysis of the available data on total non-vascular mortality might well yield an uninformatively non-significant result (as, of course, might analysis of total all cause mortality, in which any effects on particular non-vascular causes might be swamped by any effects on the much commoner vascular causes).
Despite these limitations table II presents the analyses of total non-vascular mortality. Overall there was a very slight tendency for there to be fewer nonvascular deaths among patients allocated to treatment than would have been expected if in each separate study the prognosis of the treated patients had been identical with that of their matched controls, but the difference was small (total observed among patients allocated to treatment 280; total expected 287-3 (table II) ) and wholly non-significant. As originally planned, these non-vascular deaths were excluded from all subsequent analyses of vascular event rates; nevertheless, as they indicated little or no effect of treatment their exclusion or inclusion would have had little or no effect on the main conclusions. Table III presents the main results from each trial in terms of the numbers of patients suffering important vascular events-that is, stroke or myocardial infarction or vascular death (separate analyses for these three conditions are given below). In 22 of the 25 trials these main results favoured antiplatelet treatment-that is, the number of patients allocated to treatment who were observed to suffer at least one such event was smaller than the number who would have been expected to do so if the event rates among controls and treated patients had been similar. Moreover, even in the remaining three trials the statistic observed minus expected was only slightly positive, whereas for many of the 22 trials whose results favoured treatment the statistic observed minus expected was strikingly negative, so that the grand total of all 25 observed minus expected values in table III (which would have differed only randomly from zero if treatment had done nothing in any trial) was -272-0. This is much more extremely negative than could reasonably be accounted for by chance. (The variance of this grand total was 954-6; the standard deviation is the square root of 954-6-that is, 30 9-so the grand total is 8-8 standard deviations in favour of treatment (2p<0-0001).)
OVERALL ANALYSIS OF ALL THREE TYPES OF VASCULAR EVENT
A crude way of translating the grand total of -272-0 from statistical into medical terms is simply to double it and conclude that treatment in these trials appeared to have protected about 500 or 600 patients against such an event. A more accurate way of using the grand total is suggested in the statistical methods section, which indicates that in these trials the typical reduction in the odds of suffering a vascular event was 25% (SD 3%). (Note that because of the approximate cancellation of two small correction factors that point in opposite directions, if allocation to active treatment can reduce the odds of suffering a vascular event by about a quarter then actual use of active treatment can reduce the probability of suffering a vascular event by about a quarter.)
The key point, however, is not the statistical details but the statistical principles, which do not entail any unjustifiable medical assumptions. It is not assumed that the effects in patients with a history of cerebral and cardiac events were necessarily the same size (though they did not appear to be greatly different (table III) ), nor is it assumed that different antiplatelet treatments were necessarily equivalent, and nor is it assumed that the results from each trial were precisely "correct"; indeed, in addition to any intended differences between studies in the definitions of what constituted a stroke, myocardial infarction, or vascular death, numerous other omissions and errors must have occurred in the determination of who suffered a vascular event and who did not. All that is assumed is that these potentially substantial sources of error in the results for individual patients were largely random in their effects on the treatment comparisons, so that within each trial the comparison of treatment with control was not subject to any substantial bias and that likewise no substantial bias was introduced by the choice of which randomised trials to study. (In this context "substantial" bias means bias that might plausibly account for a substantial proportion of the 25% risk reduction that the trial results collectively suggested.) Table III suggests a general consistency of the different trial results. Figure 3 displays the results from each separate trial for important vascular events together with various overviews of these trial results. The result for each trial is plotted in terms of the odds ratio (treated v control) and 99% confidence interval, using black squares whose areas indicate the amount of information contributed by each trial. Overview results are presented with their 95% confidence intervals and corresponding typical percentage odds reductions and standard deviations. The odds ratio of 0-75 suggested by the overview of all the trial results (dashed vertical line) indicates a reduction of 25% (SD 3%; table III) in the odds of suffering an important vascular event. Table III gives details of the underlying calculations. For all but five' 23 26 29 36 of the trials the odds ratio of unity (vertical solid line; no treatment effect) is crossed by the confidence interval for that trial, indicating that, taken separately, those trials did not provide clear evidence of benefit. For almost all trials, however, the point estimates are somewhat to the left of unity, suggesting some benefit, and in the overviews these separate tendencies reinforce each other to produce overwhelmingly definite evidence of benefit.
In figure 3 the confidence interval for each separate trial reaches or overlaps the 25% reduction in the odds of failure suggested by the overview of all completed trials (dashed vertical line). This suggests that no trial yielded a benefit clearly significantly better or clearly significantly worse than 25%. Indeed, though the separate trials do not all indicate exactly the same risk reduction, the amount of scatter is no greater than might be expected by chance if the true risk reduction in each study was exactly 25%.
(Formally, the statistical test for heterogeneity (table III) yielded a nonsignificant result.) This lack of significant heterogeneity of benefit is, however, of limited relevance, partly because such tests are surprisingly insensitive to any real differences that may exist between different studies, but chiefly because whatever result a formal heterogeneity test might yield it is not reasonable (and not necessary for the overview) to suppose the true risk reductions in all trials to be identical.
SUBDIVISIONS OF MAIN ANALYSIS
The main analysis entailed review of all randomised trials (irrespective of whether the criterion for entry was a history of cerebrovascular disease, of nevertheless, it was not statistically significant, and evidence other than that reviewed in this paper will be needed to resolve this issue. Tables IV and V give the results separately for non-fatal myocardial infarction and non-fatal stroke. In both cases there were risk reductions of about 30%, suggesting that use ofantiplatelet treatment-that is, with 100% compliance-might reduce the odds of suffering such non-fatal events by about one third. These risk reductions were both so significantly and substantially different from zero that the unavailability of full data from the few trials that were still in progress was unlikely to be important. For most of figure 3 were subdivided with respect to the type of prior disease, but there was no significant heterogeneity between the treatment effects achieved in the trials among patients with a history of cerebrovascular disease (22% (SD 5%)), myocardial infarction (25% (4%)), and unstable angina (36% (13%)). All differed by less than one standard deviation from the 25% reduction seen in the main analysis. The proportional risk reduction in patients with unstable angina appeared somewhat greater than that in other categories of patient, and the difference may well have been real: the non-fatal strokes in the cerebrovascular trials information was reviewed on whether the strokes were bad enough to leave substantial residual disability (Rankin grade 3 or more) six months after the event (data not shown). This review suggested that the percentage reduction conferred by antiplatelet treatment was somewhat greater for disabling than for nondisabling stroke, but from some cerebral and all cardiac trials such data were not available for review.
Differences between different measures ofoutcome
With regard to vascular death (table VI) the effects of treatment were again highly significant (3-6 standard deviations from zero; 2p=0 0003), and especially in view of the established effects of treatment on non-fatal vascular events this difference may be accepted as real. The apparent size of the risk reduction (15% (SD 4%)), however, was only about half as great as for nonfatal events, so it was particularly important to confirm the absence of any substantial sources of bias. The unavailability of data from the six trials still in progress was unlikely to be a serious source of bias because the numbers of vascular deaths in those trials had not become large enough for a premature halt to be likely. A marginally significant imbalance in prognostic features was recorded in only one large trial (AMIS) 22 and not in any other. Statistical correction for this imbalance would, however, alter the overall reduction in vascular mortality only slightly, improving it from 15% to 17% (table VI) .
One reason why the effects of treatment appeared to be less extreme for vascular death than for the non-fatal events considered in tables IV and V is possible source of data that might be used to distinguish with reasonable statistical power between the effects ofdifferent antiplatelet agents. Another source was provided by the data from the present trials on total vascular event rates (fig 3) , which may be subdivided according to the type of agent tested (table VII, fig 4) . Though vascular deaths are generally more important than vascular events, the overall effect of treatment was much clearer for events than for deaths, so any important differences between the 
VASCULAR EVENTS AND VASCULAR DEATH
In contrast, a significant (2p=00003) reduction in vascular mortality was seen (and the reduction in all cause mortality was also significant: z=3-5, 2p=00003), and both of these differences would have been slightly more significant had an appropriately adjusted analysis of the AMIS trial been used (table VI). In view of the extremely significant reductions in non-fatal myocardial infarction (2p<0-0001; table IV) and non-fatal stroke (2p<0l0001; table V) that were also seen the reduction in vascular mortality among such patients can safely be accepted as real.
DIFFERENCES BETWEEN DIFFERENT TYPES OF PATIENT
The observed benefit among patients with unstable angina was somewhat greater than that in patients with a history of myocardial Hence it might be reasonable to infer that provided that there was no special contraindication antiplatelet treatment would probably also be of net benefit for an even wider range of patients who are for some reason at particular risk of occlusive vascular disease.
Perhaps it would be possible to extrapolate too far and reach mistaken conclusions that engender inappropriate treatment. It would also, however, be possible to engender inappropriate treatment by taking too formal a view of the existing evidence and so not extrapolating far enough, thereby denying treatment to many patients who would in fact benefit. Thus the information from trials can provide guidance in the treatment of a far wider range of patients than just those studied in the trials, though the further the extrapolation the more desirable it would be to have direct evidence. So, for example, direct evidence is needed, and is currently being sought, about the value of beginning a few weeks of antiplatelet treatment immediately on admission for coronary care (ISIS39) and of aspirin in the "primary" prevention of disease among apparently healthy people whose absolute risks of occlusive events are low and among whom, therefore, even a small increase in serious haemorrhagic events might outweigh the expected decrease in occlusive events (Peto et al, accompanying paper)."
DIFFERENCES BETWEEN DIFFERENT DOSES OF ASPIRIN
The most convenient and least expensive type of antiplatelet agent is low dose aspirin. Unfortunately, we have little direct evidence about the antithrombotic effects of very low doses (for example, less than 100 mg/day'9"' 412), and all the aspirin trials in this overview that did not use 300-325 mg/day used 900-1500 mg/day. These higher doses are less convenient and more gastrotoxic than 300 mg/day (UK-TIA Study Group, accompanying paper), so they could be recommended for routine use only if there was reasonably good evidence that they were more effective. Pharmacological studies, however, suggest that cyclo-oxygenase dependent platelet aggregation is inhibited just as effectively by 300 mg of aspirin as by higher doses; indeed, some pharmacologists have suggested that doses substantially lower than 300 mg/day might actually be preferable,4"42 and doses of only 100 mg/day have a substantial antithrombotic effect in man. 43 If to reduce gastrotoxicity still further an enteric coated preparation was used then the dose should probably not be reduced much below 80 mg/day.44 Moreover, in the present set of trials the studies of 300-325 mg/day appeared to have yielded results that were at least as good as those yielded by 900-1500 mg/day (table VII, fig 4) . This comparison is indirect and the differences noted not statistically significant; nevertheless, if aspirin is to be used prophylactically in routine medical practice there appears to be no good reason to use a dose higher than 300-325 mg/day-indeed, substantially lower doses might well be at least as effective41-43 and would cause very little gastrotoxicity. (A main reason for choosing to test high daily doses in the original clinical trials of aspirin was simply that in 1970 tests for aspirin metabolites in urine were so crude that a high dose was needed to facilitate biochemical checks on compliance).
DIFFERENCES BETWEEN ANTIPLATELET AGENTS
Apart from aspirin the two main antiplatelet agents studied in these trials were sulphinpyrazone and aspirin combined with dipyridamole, and it would be desirable to know whether there are any clinically significant differences among the effects of these three agents on vascular disease. Three types of evidence may be considered.
Firstly, the results of individual trials may be singled out and considered in isolation from the rest. This common practice is plainly inappropriate, as by suitable selection of which trial to emphasise almost any claim might appear to be substantiated. (For example, the most promising result in any one trial was that from the GDR study of 1500 mg aspirin/day alone,29 but it would be inappropriate to emphasise this without also emphasising the more moderate results seen in the other trials of high dose aspirin alone.)
Secondly, separate overviews may be undertaken for sulphinpyrazone v nil (17% (SD 8%)), for high dose aspirin v nil (23% (4%)), and for aspirin plus dipyridamole v nil (31% (5%)) and the results compared. This provides an indirect comparison of three different types of treatment. In this instance the indirect comparison suggested that aspirin plus dipyridamole may possibly be superior to aspirin alone, but the comparison was not even statistically significant (31% (SD 5%) v 23% (4%); 2p>0 1), and in addition it was only indirect (table VII, fig 4) . tTrials contained more than two treatment groups; of these, only two utilised in any comparison. tExclusion of one or both sulphinpyrazone trials for which only partial information available leaves typical odds reduction for sulphinpyrazone unchanged at approximately 17%.
Test for heterogeneity among four types of treatment: x2 on 3 degrees of freedom=3-4 (NS).
Finally, some direct randomised comparisons of the three different types of treatment were available, but, though unbiased, they were too small to be reliable. In direct comparisons of aspirin v sulphinpyrazone there were 54 vascular events among patients allocated aspirin and 74 among those allocated sulphinpyrazone (table VII, fig 4) . This difference was not significant, but it certainly does not provide any evidence to justify the additional cost and increased frequency of treatment with sulphinpyrazone.
In trials comparing aspirin directly with aspirin plus dipyridamole a total of 275 vascular events occurred among patients allocated aspirin alone and 279 among those allocated aspirin plus dipyridamole, which again does not provide any direct evidence to justify the extra cost, side effects, and frequency of administration entailed by adding dipyridamole. Moreover, a recent review of the pharmacological effects of dipyridamole and of evidence from other clinical trials that compared aspirin directly with aspirin plus dipyridamole likewise concluded that there was no good evidence that adding dipyridamole was likely to confer any additional benefit.45 It is important, however, not to dismiss the apparent advantage of dipyridamole in the indirect comparisons just because it was not statistically significant and not to exaggerate the strength of the negative evidence provided by the direct comparisons. There were only 275 v 279 vascular events in the trials of aspirin v aspirin plus dipyridamole, and so though these and other data45 tend to suggest that adding dipyridamole is of little or no value, the breadth of the confidence interval (fig 4) was compatible with the suggestion that dipyridamole might somewhat increase the efficacy of aspirin but that chance just happened to obscure this benefit. What is needed is some far more extensive direct comparisons of aspirin alone (in a dose sufficient to have a strong effect on cyclo-oxygenase dependent platelet aggregation) v aspirin plus dipyridamole, for if dipyridamole does confer any significant additional advantage then it will be important not to overlook this.
There was, however, no good evidence from the trials reviewed that any of the antiplatelet treatments studied were more or less effective than any others. For the present the least expensive and most convenient antiplatelet treatment appears to be aspirin, perhaps at a dose no greater than (or even much less than) 300-325 mg/day. On current evidence it appears that the ideal formulation of prophylactic aspirin might be day marked calendar packs of enteric coated low dose aspirin that would virtually completely inhibit cyclo-oxygenase dependent platelet aggregation with minimal gastrotoxicity. At The populations in these trials were selected for study because they had a history of disease (transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction) that suggested a particular risk ofa new occlusive vascular event; and 17% of patients suffered at least one new vascular event during the trials. In principle antiplatelet treatment might be expected to decrease the incidence of serious occlusive events but to increase the incidence of serious haemorrhagic vascular events, possibly including intracerebral haemorrhage. Unfortunately, from the information available from many of the trials it was often difficult to distinguish reliably between haemorrhagic and occlusive strokes-indeed, it was sometimes difficult to distinguish reliably between fatal stroke and fatal myocardial infarction (though the distinction between vascular and non-vascular causes of death was usually fairly clear). Hence as far as the prevention of cerebrovascular disease is concerned this overview asks merely whether treatment reduces total vascular mortality and the total incidence of non-fatal stroke without further subdivision, and in each case there was a statistically significant reduction. But though it might be reasonable to extrapolate these risk reductions to a wide range of other patients who are also at particular risk of occlusive vascular events, it might be unwise to extrapolate them to people who are not at particular risk and in whom the absolute benefit would therefore be small. For it is possible-especially in view of the results of Peto et al (accompanying paper>-that for apparently healthy people any small benefits might be outweighed by a small increase in cerebral or other serious haemorrhagic disease. Hence the final entry in table IX emphasises that the absolute benefits in primary prevention remain uncertain despite the results of a study of aspirin among British doctors (Peto et al, accompanying paper) and the early results53 of a corresponding study of prophylactic aspirin among doctors in the United States.4" Taken together, those two primary prevention trials show a reduction in non-fatal myocardial infarction, but they also suggest a slight increase in disabling stroke and no net reduction in vascular deaths. Thus only for patients with an appropriate history of vascular disease is there at present clear evidence that antiplatelet treatment reduces the overall incidence of fatal or disabling vascular disease.
